Spots Global Cancer Trial Database for XmAb20717 in Advanced Biliary Tract Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: XmAb20717 in Advanced Biliary Tract Cancers
Official Title: Phase II Trial of XmAb20717 in Patients With Advanced Biliary Tract Cancers
Study ID: NCT05297903
Conditions
Interventions
Study Description
Brief Summary: This is a single-arm, phase II clinical trial to evaluate the efficacy of XmAb20717 in patients with advanced biliary tract cancers who have progressed on, or were intolerant of, a gemcitabine-based chemotherapy regimen.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact Details
Name: Thomas Karasic, MD
Affiliation: Abramson Cancer Center at Penn Medicine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
